Furthermore, treatment with the combination of fruquintinib and sintilimab significantly reduced the fraction of CD11b+Gr1+MDSCs and CD11b+F4/80+tumor-associated macrophages in CT26 allograft tumor compared to fruquintinib or sintilimab alone (Figure 3D). The gene discussed is ITGAM; the disease is neoplasm.